IDH-1
Showing 1 - 25 of >10,000
Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)
Not yet recruiting
- Cholangiocarcinoma With IDH1 Mutation
- Solid Tumors With IDH1 Mutation
- AB-218 capsule
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)
Recruiting
- Low-grade Glioma
- +4 more
- Niraparib
- Resection/Treatment with Niraparib
-
Boston, MassachusettsMassachusetts General Hospital
Oct 19, 2022
IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)
Not yet recruiting
- IDH1-mutant Cholangiocarcinoma
- Ivosidenib
- +3 more
- (no location specified)
Jun 29, 2023
Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)
Recruiting
- Recurrent IDH1/2 Mutated Glioma
-
Paris, FrancePitie Salpetriere Hospital
Aug 29, 2022
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)
Not yet recruiting
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma Metastatic
- (no location specified)
Oct 10, 2023
Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)
Active, not recruiting
- Glioma, Malignant
- Computer-Assisted
- Validation of IDH1 mutations from the radiomics model
-
Shanghai, Shanghai, ChinaHuashan Hospital, Fudan University
Jul 23, 2023
Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)
Not yet recruiting
- Brain Tumor
- Cancer
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1
Not yet recruiting
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Ivosidenib 500mg
- Placebo
- (no location specified)
Nov 7, 2023
Low Grade Glioma of Brain Trial in Durham (PEPIDH1M vaccine + vorasidenib)
Not yet recruiting
- Low Grade Glioma of Brain
- PEPIDH1M vaccine + vorasidenib
-
Durham, North CarolinaDuke University Medical Center
Nov 2, 2022
Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)
Recruiting
- Advanced Solid Tumor
- +2 more
- ivosidenib and nivolumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 14, 2022
Glioma Trial in Melbourne (Biopsy, Part A: AB-218, Surgery (maximal resection))
Recruiting
- Glioma
- Biopsy
- +3 more
-
Melbourne, Victoria, AustraliaRoyal Melbourne Hospital
Oct 11, 2022
Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Gilteritinib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2023
Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity
Recruiting
- Astrocytoma, Grade IV
- +3 more
- CYNK-001 systemic and Intra cavity administration
-
Duarte, California
- +5 more
Jan 20, 2023
Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Ivosidenib Oral Tablet
- Azacitidine
-
Vienna, Austria
- +3 more
Jun 8, 2023
IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)
Active, not recruiting
- IDH1 Mutation Myeloid Neoplasms
-
Baltimore, Maryland
- +3 more
Oct 25, 2021
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,
Not yet recruiting
- Diffuse Astrocytoma, IDH-Mutant
- +20 more
- NEO212 Oral Capsule
- +8 more
- (no location specified)
Sep 18, 2023
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)
Recruiting
- IDH Mutation
- +4 more
- Ivosidenib
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Houston (other,
Recruiting
- Anaplastic Astrocytoma, IDH-Wildtype
- +8 more
- Quality-of-Life Assessment
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 8, 2022